Item Type | Name |
Academic Article
|
Gel stretch method: a new method to measure constitutive properties of cardiac muscle cells.
|
Academic Article
|
Role of microtubules in the contractile dysfunction of hypertrophied myocardium.
|
Academic Article
|
Hypertrophic response to hemodynamic overload: role of load vs. renin-angiotensin system activation.
|
Academic Article
|
Retinoid signaling required for normal heart development regulates GATA-4 in a pathway distinct from cardiomyocyte differentiation.
|
Academic Article
|
Pressure-overload hypertrophy is unabated in mice devoid of AT1A receptors.
|
Academic Article
|
Cytoskeletal role in the transition from compensated to decompensated hypertrophy during adult canine left ventricular pressure overloading.
|
Academic Article
|
Mechanisms of cardiac hypertrophy in canine volume overload.
|
Academic Article
|
Constitutive properties of adult mammalian cardiac muscle cells.
|
Academic Article
|
Initial retinoid requirement for early avian development coincides with retinoid receptor coexpression in the precardiac fields and induction of normal cardiovascular development.
|
Academic Article
|
Abnormal anteroposterior and dorsoventral patterning of the limb bud in the absence of retinoids.
|
Academic Article
|
Beta3-integrin-mediated focal adhesion complex formation: adult cardiocytes embedded in three-dimensional polymer matrices.
|
Academic Article
|
Abnormalities of somite development in the absence of retinoic acid.
|
Academic Article
|
Microtubule depolymerization normalizes in vivo myocardial contractile function in dogs with pressure-overload left ventricular hypertrophy.
|
Academic Article
|
Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy.
|
Academic Article
|
beta-Adrenergic and endothelin receptor interaction in dilated human cardiomyopathic myocardium.
|
Academic Article
|
Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy.
|
Academic Article
|
New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment.
|
Academic Article
|
Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function.
|
Academic Article
|
Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function.
|
Academic Article
|
Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry.
|
Academic Article
|
Structural components of cardiomyocyte remodeling: summation.
|
Academic Article
|
Peter C. Gazes: physician, teacher, scholar.
|
Academic Article
|
Heart failure in aortic stenosis - improving diagnosis and treatment.
|
Academic Article
|
Heart failure with preserved ejection fraction: is this diastolic heart failure?
|
Academic Article
|
Load-dependent left ventricular relaxation in conscious dogs.
|
Academic Article
|
A novel tubular scaffold for cardiovascular tissue engineering.
|
Academic Article
|
Left ventricular function after surgical correction of chronic mitral regurgitation.
|
Academic Article
|
Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice.
|
Academic Article
|
Anterior endoderm is sufficient to rescue foregut apoptosis and heart tube morphogenesis in an embryo lacking retinoic acid.
|
Academic Article
|
Effects of left ventricular volume overload produced by mitral regurgitation on diastolic function.
|
Academic Article
|
Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure.
|
Academic Article
|
Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits.
|
Academic Article
|
Dialysis-induced alterations in left ventricular filling: mechanisms and clinical significance.
|
Academic Article
|
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study.
|
Academic Article
|
Comparison of variability associated with sample preparation in two-dimensional gel electrophoresis of cardiac tissue.
|
Academic Article
|
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
|
Academic Article
|
Regulation of Ncx1 expression. Identification of regulatory elements mediating cardiac-specific expression and up-regulation.
|
Academic Article
|
Integrin activation and focal complex formation in cardiac hypertrophy.
|
Academic Article
|
Tolerance of the hypertrophic heart to ischemia. Studies in compensated and failing dog hearts with pressure overload hypertrophy.
|
Academic Article
|
Normal myocardial function in severe right ventricular volume overload hypertrophy.
|
Academic Article
|
Preliminary report on high thoracic epidural analgesia: relationship between its therapeutic effects and myocardial blood flow as assessed by stress thallium distribution.
|
Academic Article
|
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study.
|
Academic Article
|
Left ventricular end-diastolic volume is normal in patients with heart failure and a normal ejection fraction: a renewed consensus in diastolic heart failure.
|
Academic Article
|
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
|
Academic Article
|
Mechanical loads and the isovolumic and filling indices of left ventricular relaxation.
|
Academic Article
|
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study.
|
Academic Article
|
In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium.
|
Academic Article
|
Cardiopulmonary exercise variables in diastolic versus systolic heart failure.
|
Academic Article
|
STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX.
|
Academic Article
|
Patterns of structural and functional remodeling of the left ventricle in chronic heart failure.
|
Academic Article
|
Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM).
|
Academic Article
|
Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures.
|
Academic Article
|
Irbesartan in patients with heart failure and preserved ejection fraction.
|
Academic Article
|
Quantification of protein expression changes in the aging left ventricle of Rattus norvegicus.
|
Academic Article
|
Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
|
Academic Article
|
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.
|
Academic Article
|
Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium.
|
Academic Article
|
Distribution of a neutral cardioplegic vehicle during the development of ischemic myocardial contracture.
|
Academic Article
|
Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
|
Academic Article
|
Natural history of concentric left ventricular geometry in community-dwelling older adults without heart failure during seven years of follow-up.
|
Academic Article
|
Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction.
|
Academic Article
|
Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
|
Academic Article
|
Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure.
|
Academic Article
|
Stress-shortening relations and myocardial blood flow in compensated and failing canine hearts with pressure-overload hypertrophy.
|
Academic Article
|
Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium.
|
Academic Article
|
New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function.
|
Academic Article
|
Constitutive properties of hypertrophied myocardium: cellular contribution to changes in myocardial stiffness.
|
Academic Article
|
Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment.
|
Academic Article
|
Abnormal calcium homeostasis: one mechanism in diastolic heart failure.
|
Academic Article
|
Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
|
Academic Article
|
Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications.
|
Academic Article
|
Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction.
|
Academic Article
|
Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature.
|
Academic Article
|
The Heart Failure Society of America in 2020: a vision for the future.
|
Academic Article
|
The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.
|
Academic Article
|
Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload.
|
Academic Article
|
In vivo measurements of the contributions of protein synthesis and protein degradation in regulating cardiac pressure overload hypertrophy in the mouse.
|
Academic Article
|
Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy.
|
Academic Article
|
In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial).
|
Academic Article
|
Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
|
Academic Article
|
Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency.
|
Academic Article
|
?3 integrin in cardiac fibroblast is critical for extracellular matrix accumulation during pressure overload hypertrophy in mouse.
|
Academic Article
|
Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling.
|
Academic Article
|
HFpEF: cardiovascular abnormalities not just comorbidities.
|
Academic Article
|
Membrane-associated matrix proteolysis and heart failure.
|
Academic Article
|
Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease.
|
Academic Article
|
Changes in extracellular collagen matrix alter myocardial systolic performance.
|
Academic Article
|
Myocardial infarct expansion and matrix metalloproteinase inhibition.
|
Academic Article
|
Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure.
|
Academic Article
|
Depressed contractile function due to canine mitral regurgitation improves after correction of the volume overload.
|
Academic Article
|
Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes.
|
Academic Article
|
Diastolic heart failure. Diagnosis, prognosis, treatment.
|
Academic Article
|
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
|
Academic Article
|
Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.
|
Academic Article
|
Relation of N-terminal pro-B-type natriuretic peptide with diastolic function in hypertensive heart disease.
|
Academic Article
|
Mechanical determinants of maximum isotonic lengthening rate in rat left ventricular myocardium.
|
Academic Article
|
Tachycardia-induced cardiomyopathy: effects on blood flow and capillary structure.
|
Academic Article
|
Contribution of reduced mitral regurgitant volume to vasodilator effect in severe left ventricular failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy.
|
Academic Article
|
Evaluation of myocardial function in cardiomyopathic states.
|
Academic Article
|
Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia.
|
Academic Article
|
A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.
|
Academic Article
|
Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function.
|
Academic Article
|
Myocardial Na+,K(+)-ATPase in tachycardia induced cardiomyopathy.
|
Academic Article
|
Growth effects of electrically stimulated contraction on adult feline cardiocytes in primary culture.
|
Academic Article
|
Load effects on gene expression during cardiac hypertrophy.
|
Academic Article
|
Direct effects of acute administration of 3, 5, 3' triiodo-L-thyronine on myocyte function.
|
Academic Article
|
Effects of protamine on myocyte contractile function and beta-adrenergic responsiveness.
|
Academic Article
|
Structural basis for changes in left ventricular function and geometry because of chronic mitral regurgitation and after correction of volume overload.
|
Academic Article
|
The effects of complete versus incomplete mitral valve repair in experimental mitral regurgitation.
|
Academic Article
|
Native beta-adrenergic support for left ventricular dysfunction in experimental mitral regurgitation normalizes indexes of pump and contractile function.
|
Academic Article
|
Left ventricular hypertrophy due to volume overload versus pressure overload.
|
Academic Article
|
Contractile properties of isolated porcine ventricular myocytes.
|
Academic Article
|
Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance.
|
Academic Article
|
Aortic valve resistance as an adjunct to the Gorlin formula in assessing the severity of aortic stenosis in symptomatic patients.
|
Academic Article
|
Effect of chronic supraventricular tachycardia on left ventricular function and structure in newborn pigs.
|
Academic Article
|
Effects of pressure- or volume-overload hypertrophy on passive stiffness in isolated adult cardiac muscle cells.
|
Academic Article
|
Cytoskeletal mechanics in pressure-overload cardiac hypertrophy.
|
Academic Article
|
Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience.
|
Academic Article
|
Left ventricular diastolic dysfunction and diastolic heart failure.
|
Academic Article
|
Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle.
|
Academic Article
|
A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design.
|
Academic Article
|
Lack of relationship between Doppler indices of diastolic function and left ventricular pressure transients in patients with definite diastolic heart failure.
|
Academic Article
|
Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition.
|
Academic Article
|
Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.
|
Academic Article
|
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure.
|
Academic Article
|
Diastolic heart failure: definitions and terminology.
|
Academic Article
|
The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
|
Academic Article
|
Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure.
|
Academic Article
|
Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients.
|
Academic Article
|
Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function.
|
Academic Article
|
A multidimensional proteomic approach to identify hypertrophy-associated proteins.
|
Academic Article
|
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study.
|
Academic Article
|
Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
|
Academic Article
|
New molecular mechanism in diastolic heart failure.
|
Academic Article
|
Chronic aortic and mitral regurgitation. Choosing the optimal time for surgical correction.
|
Academic Article
|
Chronic heart failure: a report from the Dartmouth Diastole Discourses.
|
Academic Article
|
Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction.
|
Academic Article
|
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.
|
Academic Article
|
Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension.
|
Academic Article
|
Myocardial mechanisms causing heart failure early after cardiac transplantation.
|
Academic Article
|
Preload does not affect relaxation rate in normal, hypoxic, or hypertrophic myocardium.
|
Academic Article
|
Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients.
|
Academic Article
|
Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure.
|
Academic Article
|
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).
|
Academic Article
|
Selective translation of mRNAs in the left ventricular myocardium of the mouse in response to acute pressure overload.
|
Academic Article
|
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
|
Academic Article
|
Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial.
|
Academic Article
|
A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart.
|
Academic Article
|
Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial.
|
Academic Article
|
Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing.
|
Academic Article
|
Beta3 integrin-mediated ubiquitination activates survival signaling during myocardial hypertrophy.
|
Academic Article
|
Calpain inhibition preserves myocardial structure and function following myocardial infarction.
|
Academic Article
|
Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure.
|
Academic Article
|
Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing.
|
Academic Article
|
Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic flow therapy) in patients hospitalized with severe heart failure: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM).
|
Academic Article
|
Chronic ambulatory intracardiac pressures and future heart failure events.
|
Academic Article
|
Fabrication and characterization of bio-engineered cardiac pseudo tissues.
|
Academic Article
|
Hemodynamic factors associated with acute decompensated heart failure: part 1--insights into pathophysiology.
|
Academic Article
|
Hemodynamic factors associated with acute decompensated heart failure: part 2--use in automated detection.
|
Academic Article
|
The effect of acute alterations in left ventricular afterload and beta-adrenergic tone on indices of early diastolic filling rate.
|
Academic Article
|
Left ventricular diastolic function and exercise capacity in community-dwelling adults =65 years of age without heart failure.
|
Academic Article
|
Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
|
Academic Article
|
The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension.
|
Academic Article
|
Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial.
|
Academic Article
|
Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry.
|
Academic Article
|
Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.
|
Academic Article
|
Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
|
Academic Article
|
Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis.
|
Academic Article
|
Effects of autonomic modulation: more than just blood pressure.
|
Academic Article
|
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
|
Academic Article
|
Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing.
|
Academic Article
|
Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes.
|
Academic Article
|
Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction.
|
Academic Article
|
Neuromodulation device therapy for treatment of hypertensive heart disease.
|
Academic Article
|
Integrating the myocardial matrix into heart failure recognition and management.
|
Academic Article
|
Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements.
|
Academic Article
|
Left ventricular stress-dimension-shortening relations before and after correction of chronic aortic and mitral regurgitation.
|
Academic Article
|
Hemodynamic correlates of left ventricular versus right ventricular radionuclide volumetric responses to vasodilator therapy in congestive heart failure secondary to ischemic or dilated cardiomyopathy.
|
Academic Article
|
Serial changes in left ventricular function after correction of chronic aortic regurgitation. Dependence on early changes in preload and subsequent regression of hypertrophy.
|
Academic Article
|
Vasodilator effect on right ventricular function in congestive heart failure and pulmonary hypertension: end-systolic pressure--volume relation.
|
Academic Article
|
Chronic mitral regurgitation: predictive value of preoperative echocardiographic indexes of left ventricular function and wall stress.
|
Academic Article
|
Immunologic tests of value in diagnosis. 1. Acute phase reactants and autoantibodies.
|
Academic Article
|
Immunologic tests of value in diagnosis. 2. Complement.
|
Academic Article
|
Effects of chronic supraventricular pacing tachycardia on relaxation rate in isolated cardiac muscle cells.
|
Academic Article
|
Cellular and molecular alterations in the beta adrenergic system with cardiomyopathy induced by tachycardia.
|
Academic Article
|
Left ventricular volume determined echocardiographically by assuming a constant left ventricular epicardial long-axis/short-axis dimension ratio throughout the cardiac cycle.
|
Academic Article
|
The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy.
|
Academic Article
|
Effect of catheter positioning on the variability of measured gradient in aortic stenosis.
|
Academic Article
|
Effects of chronic mitral regurgitation on diastolic function in isolated cardiocytes.
|
Academic Article
|
Left ventricular mechanics and myocyte function after correction of experimental chronic mitral regurgitation by combined mitral valve replacement and preservation of the native mitral valve apparatus.
|
Academic Article
|
Left ventricular hypertrophy in a canine model of reversible pressure overload.
|
Academic Article
|
Comparative effects of contraction and angiotensin II on growth of adult feline cardiocytes in primary culture.
|
Academic Article
|
Effects of anisosmotic stress on cardiac muscle cell length, diameter, area, and sarcomere length.
|
Concept
|
Microscopy, Electron, Scanning
|
Concept
|
Protein-Tyrosine Kinases
|
Concept
|
Cytokines
|
Concept
|
Body Mass Index
|
Concept
|
Tacrolimus
|
Concept
|
Muscle, Smooth, Vascular
|
Concept
|
Insulin
|
Concept
|
Matrix Metalloproteinase 14
|
Concept
|
Bupivacaine
|
Concept
|
Enzyme-Linked Immunosorbent Assay
|
Concept
|
Protein Binding
|
Concept
|
Extracellular Matrix
|
Concept
|
Activities of Daily Living
|
Concept
|
Age Factors
|
Concept
|
Neutrophils
|
Concept
|
Russia
|
Concept
|
Triiodothyronine, Reverse
|
Concept
|
Disease Models, Animal
|
Concept
|
Precision Medicine
|
Concept
|
Myocardial Ischemia
|
Concept
|
Ambulatory Care
|
Concept
|
Receptors, Adrenergic, beta-2
|
Concept
|
Interleukin-10
|
Concept
|
Calcium Channel Blockers
|
Concept
|
Necrosis
|
Concept
|
Aortic Valve
|
Concept
|
Temperature
|
Concept
|
Exercise Therapy
|
Concept
|
Echocardiography, Doppler, Color
|
Concept
|
Databases, Factual
|
Concept
|
Glucuronic Acid
|
Concept
|
Rats, Inbred WKY
|
Concept
|
Heart Arrest
|
Concept
|
Patient Selection
|
Concept
|
DNA-Binding Proteins
|
Concept
|
Cardiography, Impedance
|
Concept
|
Aortic Valve Insufficiency
|
Concept
|
Transforming Growth Factor beta
|
Concept
|
Microscopy, Electron
|
Concept
|
Blood Urea Nitrogen
|
Concept
|
Terminology as Topic
|
Concept
|
Life Expectancy
|
Concept
|
NF-kappa B
|
Concept
|
Angina Pectoris
|
Concept
|
Blood Pressure
|
Concept
|
Ouabain
|
Concept
|
Cardiac Volume
|
Concept
|
Protein Processing, Post-Translational
|
Concept
|
Kaplan-Meier Estimate
|
Concept
|
Adrenergic beta-Agonists
|
Concept
|
Amnesia
|
Concept
|
Nitrates
|
Concept
|
Sus scrofa
|
Concept
|
Animals, Newborn
|
Concept
|
Muscle Proteins
|
Concept
|
Diacetyl
|
Concept
|
Sodium Potassium Chloride Symporter Inhibitors
|
Concept
|
Hydrogels
|
Concept
|
Tricuspid Valve Insufficiency
|
Concept
|
Immunity, Cellular
|
Concept
|
Tissue Scaffolds
|
Concept
|
Fibroblast Growth Factor 8
|
Concept
|
Mitochondria
|
Concept
|
Osteopontin
|
Concept
|
Hospice Care
|
Concept
|
Echocardiography, Doppler
|
Concept
|
Lymphangiogenesis
|
Concept
|
Circadian Rhythm
|
Concept
|
Patient Dropouts
|
Concept
|
Heart Failure, Systolic
|
Concept
|
Incidence
|
Concept
|
Dobutamine
|
Concept
|
Proportional Hazards Models
|
Concept
|
Mitogen-Activated Protein Kinases
|
Concept
|
Recurrence
|
Concept
|
Drug Discovery
|
Concept
|
Sphingolipids
|
Concept
|
Embryo, Mammalian
|
Concept
|
Morbidity
|
Concept
|
Lactic Acid
|
Concept
|
Quebec
|
Concept
|
Hypothermia, Induced
|
Concept
|
Heart Septal Defects, Atrial
|
Concept
|
Hospices
|
Concept
|
Geography
|
Concept
|
Cell Division
|
Concept
|
Heart Valve Prosthesis Implantation
|
Concept
|
Cardiac Output, Low
|
Concept
|
Collagenases
|
Concept
|
Body Size
|
Concept
|
Fibrinolytic Agents
|
Concept
|
Magnetic Resonance Imaging
|
Concept
|
Actins
|
Concept
|
Sex Distribution
|
Concept
|
Gene Expression
|
Concept
|
Polymers
|
Concept
|
Matrix Metalloproteinase 1
|
Concept
|
Myosins
|
Concept
|
Oligonucleotide Probes
|
Concept
|
Receptors, Endothelin
|
Concept
|
Warfarin
|
Concept
|
Patient Care Team
|
Concept
|
Diabetes Complications
|
Concept
|
Colloids
|
Concept
|
Cats
|
Concept
|
Manometry
|
Concept
|
Canada
|
Concept
|
Models, Economic
|
Concept
|
Dietary Fats
|
Concept
|
Lactates
|
Concept
|
Isoproterenol
|
Concept
|
Minnesota
|
Concept
|
Pyrazoles
|
Concept
|
Fluorescent Antibody Technique
|
Concept
|
Sodium-Calcium Exchanger
|
Concept
|
Myocarditis
|
Concept
|
Body Weight
|
Concept
|
Disease Progression
|
Concept
|
Contractile Proteins
|
Concept
|
Hypoglycemic Agents
|
Concept
|
Drug Approval
|
Concept
|
Radiopharmaceuticals
|
Concept
|
Hedgehog Proteins
|
Concept
|
Sensitivity and Specificity
|
Concept
|
Death, Sudden, Cardiac
|
Concept
|
Medication Therapy Management
|
Concept
|
Vascular Cell Adhesion Molecule-1
|
Concept
|
Endothelium, Vascular
|
Concept
|
Electric Stimulation Therapy
|
Concept
|
Aorta, Thoracic
|
Concept
|
Receptors, Cell Surface
|
Concept
|
Patient Discharge
|
Concept
|
Single-Blind Method
|
Concept
|
Catecholamines
|
Concept
|
Electrophoresis, Gel, Two-Dimensional
|
Concept
|
Cell Adhesion
|
Concept
|
Heart Transplantation
|
Concept
|
Intrinsic Factor
|
Concept
|
Registries
|
Concept
|
Gelatinases
|
Concept
|
Sodium-Potassium-Exchanging ATPase
|
Concept
|
Treatment Outcome
|
Concept
|
Macrophages
|
Concept
|
Kidney Failure, Chronic
|
Concept
|
Angioplasty, Balloon, Coronary
|
Concept
|
National Institutes of Health (U.S.)
|
Concept
|
Genes, Dominant
|
Concept
|
Bone Marrow Transplantation
|
Concept
|
Tretinoin
|
Concept
|
GTP-Binding Proteins
|
Concept
|
Clinical Trials, Phase III as Topic
|
Concept
|
Cricetinae
|
Concept
|
Administration, Oral
|
Concept
|
Fibronectins
|
Concept
|
Polyribosomes
|
Concept
|
Receptors, Mitogen
|
Concept
|
Potassium
|
Concept
|
Glycation End Products, Advanced
|
Concept
|
Collagen Type I
|
Concept
|
Research Design
|
Concept
|
Confidence Intervals
|
Concept
|
Dogs
|
Concept
|
Chagas Disease
|
Concept
|
Thoracic Vertebrae
|
Concept
|
Sirolimus
|
Concept
|
Antibodies, Antinuclear
|
Concept
|
Pulmonary Valve Insufficiency
|
Concept
|
Myosin Heavy Chains
|
Concept
|
Animals
|
Concept
|
Chi-Square Distribution
|
Concept
|
GATA6 Transcription Factor
|
Concept
|
Syndrome
|
Concept
|
Feasibility Studies
|
Concept
|
Computer Simulation
|
Concept
|
Myocardial Revascularization
|
Concept
|
Terminal Care
|
Concept
|
Mitogen-Activated Protein Kinase 1
|
Concept
|
Oncogene Proteins
|
Concept
|
Postoperative Care
|
Concept
|
Hexuronic Acids
|
Concept
|
Blood Pressure Monitors
|
Concept
|
Chronic Disease
|
Concept
|
Angina, Unstable
|
Concept
|
Adrenergic beta-Antagonists
|
Concept
|
Electrophysiology
|
Concept
|
Societies, Medical
|
Concept
|
Carbon Radioisotopes
|
Concept
|
Developing Countries
|
Concept
|
Double-Blind Method
|
Concept
|
Trans-Activators
|
Concept
|
Adenosine Triphosphate
|
Concept
|
Protein Biosynthesis
|
Concept
|
Triiodobenzoic Acids
|
Concept
|
Disease-Free Survival
|
Concept
|
Algorithms
|
Concept
|
Biopolymers
|
Concept
|
Health Status
|
Concept
|
Random Allocation
|
Concept
|
Mice, Knockout
|
Concept
|
Geriatric Assessment
|
Concept
|
Immunosuppressive Agents
|
Concept
|
Vasodilator Agents
|
Concept
|
Bundle-Branch Block
|
Concept
|
Hydroxamic Acids
|
Concept
|
Cohort Studies
|
Concept
|
Complement Pathway, Classical
|
Concept
|
Antibodies
|
Concept
|
Sarcolemma
|
Concept
|
Quail
|
Concept
|
Tachycardia
|
Concept
|
Receptors, Angiotensin
|
Concept
|
Natriuretic Peptide, Brain
|
Concept
|
Coronary Artery Disease
|
Concept
|
Myocytes, Cardiac
|
Concept
|
Cell Respiration
|
Concept
|
Electric Impedance
|
Concept
|
Stroke
|
Concept
|
Sample Size
|
Concept
|
Mortality
|
Concept
|
Genes, fos
|
Concept
|
Culture Media
|
Concept
|
Death, Sudden
|
Concept
|
Calcium
|
Concept
|
Adenylyl Cyclases
|
Concept
|
United States Department of Veterans Affairs
|
Concept
|
Intracellular Membranes
|
Concept
|
Acute Disease
|
Concept
|
Propranolol
|
Concept
|
Pulmonary Artery
|
Concept
|
Troponin
|
Concept
|
STAT3 Transcription Factor
|
Concept
|
Chemotaxis
|
Concept
|
Blotting, Western
|
Concept
|
Analgesics, Opioid
|
Concept
|
C-Reactive Protein
|
Concept
|
Angioedema
|
Concept
|
Sarcomeres
|
Concept
|
Protein Precursors
|
Concept
|
Regression Analysis
|
Concept
|
Cardiomyopathies
|
Concept
|
Arteries
|
Concept
|
Injections, Subcutaneous
|
Concept
|
Ferricyanides
|
Concept
|
Heart Failure
|
Concept
|
Myocardial Infarction
|
Concept
|
Spironolactone
|
Concept
|
Diabetes Mellitus
|
Concept
|
Constriction
|
Concept
|
Heart Defects, Congenital
|
Concept
|
Microtomy
|
Concept
|
Retinoids
|
Concept
|
Genetic Predisposition to Disease
|
Concept
|
Disease Management
|
Concept
|
Hydrochlorothiazide
|
Concept
|
Diabetic Nephropathies
|
Concept
|
Microtubules
|
Concept
|
Aminobutyrates
|
Concept
|
Integrin beta3
|
Concept
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
Concept
|
Biopsy
|
Concept
|
Myocardium
|
Concept
|
Coronary Angiography
|
Concept
|
S100 Proteins
|
Concept
|
GATA4 Transcription Factor
|
Concept
|
Dose-Response Relationship, Drug
|
Concept
|
Cranial Sinuses
|
Concept
|
Asia
|
Concept
|
Extracellular Matrix Proteins
|
Concept
|
Clinical Protocols
|
Concept
|
Shc Signaling Adaptor Proteins
|
Concept
|
Infusions, Intravenous
|
Concept
|
Postoperative Complications
|
Concept
|
Vascular Endothelial Growth Factor D
|
Concept
|
Caspase 3
|
Concept
|
Obesity
|
Concept
|
Energy Metabolism
|
Concept
|
Logistic Models
|
Concept
|
Angiotensins
|
Concept
|
Chromatography, Gel
|
Concept
|
Intracellular Signaling Peptides and Proteins
|
Concept
|
Enzyme Induction
|
Concept
|
Procollagen
|
Concept
|
Natriuretic Peptides
|
Concept
|
Galectin 3
|
Concept
|
Mice
|
Concept
|
Contrast Media
|
Concept
|
Electrodes, Implanted
|
Concept
|
Cardiovascular Agents
|
Concept
|
Arrhythmias, Cardiac
|
Concept
|
Synovial Fluid
|
Concept
|
Clinical Trials as Topic
|
Concept
|
Nitroprusside
|
Concept
|
Aortic Valve Stenosis
|
Concept
|
Diastole
|
Concept
|
Models, Biological
|
Concept
|
Neprilysin
|
Concept
|
Epilepsy
|
Concept
|
Rats, Inbred SHR
|
Concept
|
Vitamin A
|
Concept
|
Statistics, Nonparametric
|
Concept
|
Ventricular Fibrillation
|
Concept
|
Linear Models
|
Concept
|
Computer-Aided Design
|
Concept
|
Neutral Ceramidase
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
Concept
|
Sympathetic Nervous System
|
Concept
|
Hypertrophy, Left Ventricular
|
Concept
|
Transcription, Genetic
|
Concept
|
Echocardiography
|
Concept
|
Microscopy, Confocal
|
Concept
|
Pacemaker, Artificial
|
Concept
|
Histone Deacetylases
|
Concept
|
Angiotensin II Type 1 Receptor Blockers
|
Concept
|
Coronary Artery Bypass
|
Concept
|
Renin
|
Concept
|
Antihypertensive Agents
|
Concept
|
Europe, Eastern
|
Concept
|
Glomerulonephritis
|
Concept
|
Xenopus Proteins
|
Concept
|
Intra-Aortic Balloon Pumping
|
Concept
|
Matrix Metalloproteinase 9
|
Concept
|
Hypertrophy, Right Ventricular
|
Concept
|
Capillaries
|
Concept
|
Tissue Engineering
|
Concept
|
Immediate-Early Proteins
|
Concept
|
Furosemide
|
Concept
|
Receptors, Adrenergic, beta
|
Concept
|
Diabetes Mellitus, Type 2
|
Concept
|
Matrix Metalloproteinase 2
|
Concept
|
Sarcoplasmic Reticulum
|
Concept
|
Treatment Failure
|
Concept
|
Defibrillators, Implantable
|
Concept
|
Complement System Proteins
|
Concept
|
Mice, Inbred C57BL
|
Concept
|
Regulatory Sequences, Nucleic Acid
|
Concept
|
Captopril
|
Concept
|
Bone Morphogenetic Proteins
|
Concept
|
Lysine
|
Concept
|
Polycystic Kidney, Autosomal Dominant
|
Concept
|
Retrospective Studies
|
Concept
|
Proto-Oncogene Proteins c-akt
|
Concept
|
Growth Differentiation Factor 15
|
Concept
|
Tissue Inhibitor of Metalloproteinase-2
|
Concept
|
Endoderm
|
Concept
|
Multicenter Studies as Topic
|
Concept
|
Cost Savings
|
Concept
|
Models, Statistical
|
Concept
|
Cells, Cultured
|
Concept
|
Dangerous Behavior
|
Concept
|
Mineralocorticoid Receptor Antagonists
|
Concept
|
Biocompatible Materials
|
Concept
|
Cardiac Glycosides
|
Concept
|
Tachycardia, Supraventricular
|
Concept
|
Tyrosine
|
Concept
|
Fontan Procedure
|
Concept
|
Hospital Mortality
|
Concept
|
Mice, Transgenic
|
Concept
|
Cell Separation
|
Concept
|
Isomerism
|
Concept
|
Mitochondria, Heart
|
Concept
|
Proteins
|
Concept
|
Parasympathetic Nervous System
|
Concept
|
Myofibrils
|
Concept
|
Matrix Metalloproteinase 13
|
Concept
|
Multivariate Analysis
|
Concept
|
Oxygen
|
Concept
|
Early Growth Response Protein 1
|
Concept
|
Mitral Valve Insufficiency
|
Concept
|
Limb Buds
|
Concept
|
Quality of Life
|
Concept
|
Antigens, CD
|
Concept
|
Heart Septum
|
Concept
|
Adenosine
|
Concept
|
Isotope Labeling
|
Concept
|
Heart Rate
|
Concept
|
Monocytes
|
Concept
|
Hospitalization
|
Concept
|
Proteinuria
|
Concept
|
Ventricular Dysfunction, Left
|
Concept
|
Exercise
|
Concept
|
Intestine, Small
|
Concept
|
Severity of Illness Index
|
Concept
|
RNA, Messenger
|
Concept
|
Patient Care Planning
|
Concept
|
Cell Proliferation
|
Concept
|
Collagen Type III
|
Concept
|
Survival Rate
|
Concept
|
Humans
|
Concept
|
Palmitic Acids
|
Concept
|
Heart
|
Concept
|
Doxorubicin
|
Concept
|
Receptors, CXCR3
|
Concept
|
Patient Admission
|
Concept
|
Transgenes
|
Concept
|
Organ Size
|
Concept
|
Cell Movement
|
Concept
|
Laminin
|
Concept
|
Heart Conduction System
|
Concept
|
Homeodomain Proteins
|
Concept
|
Pilot Projects
|
Concept
|
Receptor, Angiotensin, Type 1
|
Concept
|
Sphingosine N-Acyltransferase
|
Concept
|
Methods
|
Concept
|
Focal Adhesion Kinase 2
|
Concept
|
Cardiomyopathy, Hypertrophic
|
Concept
|
Europe
|
Concept
|
Proto-Oncogene Proteins c-sis
|
Concept
|
Drug Monitoring
|
Concept
|
History, 20th Century
|
Concept
|
Retinoid X Receptors
|
Concept
|
Angiotensinogen
|
Concept
|
Hospitals
|
Concept
|
Ventricular Dysfunction
|
Concept
|
Integrin beta1
|
Concept
|
Egtazic Acid
|
Concept
|
Adaptor Proteins, Signal Transducing
|
Concept
|
Cardiomegaly
|
Concept
|
Radioligand Assay
|
Concept
|
Angioplasty, Balloon
|
Concept
|
Longitudinal Studies
|
Concept
|
TRPP Cation Channels
|
Concept
|
Heart Atria
|
Concept
|
Colforsin
|
Concept
|
Zinc Fingers
|
Concept
|
Heart Failure, Diastolic
|
Concept
|
Calpain
|
Concept
|
Benzenesulfonates
|
Concept
|
Cysteine Proteinase Inhibitors
|
Concept
|
Anesthetics, Local
|
Concept
|
Home Care Services
|
Concept
|
Odds Ratio
|
Concept
|
Massachusetts
|
Concept
|
Heart-Assist Devices
|
Concept
|
Genes, Reporter
|
Concept
|
Confusion
|
Concept
|
Macrophages, Peritoneal
|
Concept
|
Autoantibodies
|
Concept
|
Postoperative Period
|
Concept
|
Inflammation
|
Concept
|
Asia, Southeastern
|
Concept
|
Chemokine CX3CL1
|
Concept
|
Cause of Death
|
Concept
|
American Heart Association
|
Concept
|
Blood Glucose
|
Concept
|
Myocardial Reperfusion Injury
|
Concept
|
Matrix Metalloproteinase 7
|
Concept
|
Aorta
|
Concept
|
Radiographic Image Interpretation, Computer-Assisted
|
Concept
|
Sympathectomy
|
Concept
|
Propensity Score
|
Concept
|
Atrial Fibrillation
|
Concept
|
Los Angeles
|
Concept
|
Health Care Costs
|
Concept
|
Heart Arrest, Induced
|
Concept
|
Chemokine CCL5
|
Concept
|
Tetralogy of Fallot
|
Concept
|
Sinoatrial Node
|
Concept
|
Delirium
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
Concept
|
Fibrinolysin
|
Concept
|
Survival Analysis
|
Concept
|
Systole
|
Concept
|
Arthritis, Rheumatoid
|
Concept
|
Norepinephrine
|
Concept
|
Electrolytes
|
Concept
|
Angiotensin II
|
Concept
|
Analysis of Variance
|
Concept
|
Weight Loss
|
Concept
|
Guanylate Cyclase
|
Concept
|
Body Water
|
Concept
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
|
Concept
|
Models, Animal
|
Concept
|
Protease Inhibitors
|
Concept
|
Histone Deacetylase Inhibitors
|
Concept
|
Gold
|
Concept
|
Rheumatoid Factor
|
Concept
|
Cell Culture Techniques
|
Concept
|
Troponin T
|
Concept
|
Platelet Aggregation Inhibitors
|
Concept
|
Fibroblast Growth Factor 4
|
Concept
|
Epidemiologic Research Design
|
Concept
|
Cyclosporine
|
Concept
|
Preoperative Care
|
Concept
|
Meta-Analysis as Topic
|
Concept
|
Proto-Oncogene Proteins pp60(c-src)
|
Concept
|
Coturnix
|
Concept
|
Inhibitor of Apoptosis Proteins
|
Concept
|
Water-Electrolyte Balance
|
Concept
|
Cost-Benefit Analysis
|
Concept
|
Cross-Linking Reagents
|
Concept
|
Cytoskeleton
|
Concept
|
Tubulin
|
Concept
|
Coronary Disease
|
Concept
|
Takotsubo Cardiomyopathy
|
Concept
|
Anti-Arrhythmia Agents
|
Concept
|
Fibroblast Growth Factors
|
Concept
|
Influenza Vaccines
|
Concept
|
Blood Chemical Analysis
|
Concept
|
Gelsolin
|
Concept
|
Carotenoids
|
Concept
|
Diuretics
|
Concept
|
Medicare
|
Concept
|
Oligonucleotides, Antisense
|
Concept
|
South Carolina
|
Concept
|
Platelet Membrane Glycoproteins
|
Concept
|
Angiotensin-Converting Enzyme Inhibitors
|
Concept
|
Pressoreceptors
|
Concept
|
Physical Endurance
|
Concept
|
Rats, Inbred F344
|
Concept
|
Models, Structural
|
Concept
|
Alabama
|
Concept
|
Lymph Nodes
|
Concept
|
Dementia
|
Concept
|
Adenoviridae
|
Concept
|
Prevalence
|
Concept
|
Case-Control Studies
|
Concept
|
Baroreflex
|
Concept
|
Patient Compliance
|
Concept
|
Chagas Cardiomyopathy
|
Concept
|
Hospital Costs
|
Concept
|
Palliative Care
|
Concept
|
Models, Cardiovascular
|
Concept
|
Chordae Tendineae
|
Concept
|
Albuminuria
|
Concept
|
Aortic Aneurysm, Thoracic
|
Concept
|
Insulin-Like Growth Factor Binding Proteins
|
Concept
|
Predictive Value of Tests
|
Concept
|
Reproducibility of Results
|
Concept
|
Health Status Disparities
|
Concept
|
Fumarates
|
Concept
|
Hospitals, University
|
Concept
|
Telemetry
|
Concept
|
New York
|
Concept
|
Endothelin-1
|
Concept
|
Complement Activation
|
Concept
|
Prospective Studies
|
Concept
|
United Kingdom
|
Concept
|
Complement Pathway, Alternative
|
Concept
|
Wnt Proteins
|
Concept
|
Cross-Sectional Studies
|
Concept
|
Rats
|
Concept
|
Collagen Type IV
|
Concept
|
Collagen
|
Concept
|
Least-Squares Analysis
|
Concept
|
Lactosylceramides
|
Concept
|
Diabetes Mellitus, Type 1
|
Concept
|
Fluorobenzenes
|
Concept
|
Ventricular Dysfunction, Right
|
Concept
|
I-kappa B Proteins
|
Concept
|
Mitral Valve
|
Concept
|
Anticoagulants
|
Concept
|
Digoxin
|
Concept
|
Focal Adhesion Protein-Tyrosine Kinases
|
Concept
|
Image Processing, Computer-Assisted
|
Concept
|
Biphenyl Compounds
|
Concept
|
Radionuclide Ventriculography
|
Concept
|
Blood Sedimentation
|
Concept
|
Carotid Arteries
|
Concept
|
Microscopy, Immunoelectron
|
Concept
|
Infant, Newborn
|
Concept
|
Sequence Homology, Nucleic Acid
|
Concept
|
In Situ Hybridization
|
Concept
|
Randomized Controlled Trials as Topic
|
Concept
|
Acetates
|
Concept
|
Evidence-Based Medicine
|
Concept
|
Cardiotonic Agents
|
Concept
|
Prediabetic State
|
Concept
|
Podocytes
|
Concept
|
Integrins
|
Concept
|
Losartan
|
Concept
|
GATA5 Transcription Factor
|
Concept
|
Proteomics
|
Concept
|
Creatinine
|
Concept
|
Digitalis Glycosides
|
Concept
|
Surveys and Questionnaires
|
Concept
|
Fibrosis
|
Concept
|
Enzyme Inhibitors
|
Concept
|
Muscle Weakness
|
Concept
|
Cell Line
|
Concept
|
Blood Pressure Monitoring, Ambulatory
|
Concept
|
Nitric Oxide Synthase Type II
|
Concept
|
Proto-Oncogene Proteins c-fos
|
Concept
|
Analgesics
|
Concept
|
Walking
|
Concept
|
Cardiomyopathy, Alcoholic
|
Concept
|
Heart Ventricles
|
Concept
|
Practice Patterns, Physicians'
|
Concept
|
Influenza A virus
|
Concept
|
Radiography, Interventional
|
Concept
|
Chimera
|
Concept
|
Body Patterning
|
Concept
|
Rats, Sprague-Dawley
|
Concept
|
Peptidyl-Dipeptidase A
|
Concept
|
Length of Stay
|
Concept
|
Swine
|
Concept
|
Adaptor Proteins, Vesicular Transport
|
Concept
|
United States
|
Concept
|
Protein Isoforms
|
Concept
|
Heart Valve Diseases
|
Concept
|
Probability
|
Concept
|
Bayes Theorem
|
Concept
|
Guanosine Monophosphate
|
Concept
|
Vaccination
|
Concept
|
Exercise Test
|
Concept
|
Sulfonamides
|
Concept
|
Diabetic Angiopathies
|
Concept
|
Myocardial Contraction
|
Concept
|
Asia, Western
|
Concept
|
Arterioles
|
Concept
|
United States Food and Drug Administration
|
Concept
|
Gene Deletion
|
Concept
|
Telemedicine
|
Concept
|
Risk Assessment
|
Concept
|
Exercise Tolerance
|
Concept
|
Databases, Protein
|
Concept
|
Cardiomyopathy, Dilated
|
Concept
|
Tachycardia, Ventricular
|
Concept
|
Testis
|
Concept
|
Risk
|
Concept
|
MicroRNAs
|
Concept
|
Myristic Acid
|
Concept
|
Fibrillar Collagens
|
Concept
|
Risk Factors
|
Concept
|
Weight Gain
|
Concept
|
Bone Morphogenetic Protein 2
|
Concept
|
Promoter Regions, Genetic
|
Concept
|
Receptors, CCR2
|
Concept
|
Patient Readmission
|
Concept
|
Vitamin A Deficiency
|
Concept
|
Proto-Oncogene Proteins
|
Concept
|
Gels
|
Concept
|
Dextrans
|
Concept
|
Metalloendopeptidases
|
Concept
|
Blood Proteins
|
Concept
|
Sweden
|
Concept
|
Cyclic AMP
|
Concept
|
Base Sequence
|
Concept
|
Carotid Sinus
|
Concept
|
Papillary Muscles
|
Concept
|
Follow-Up Studies
|
Concept
|
Disorders of Excessive Somnolence
|
Concept
|
Gene Knockdown Techniques
|
Concept
|
Heart Diseases
|
Concept
|
Immunohistochemistry
|
Concept
|
Compliance
|
Concept
|
Comorbidity
|
Concept
|
Insurance Benefits
|
Concept
|
Cold Temperature
|
Concept
|
Injections, Intravenous
|
Concept
|
Neurotransmitter Agents
|
Concept
|
Actin Cytoskeleton
|
Concept
|
Mathematics
|
Concept
|
Molecular Sequence Data
|
Concept
|
Congresses as Topic
|
Concept
|
Cardiac-Gated Imaging Techniques
|
Concept
|
Immunoblotting
|
Concept
|
Electrocardiography
|
Concept
|
Genes, Immediate-Early
|
Concept
|
Cell Count
|
Concept
|
Galectins
|
Concept
|
Somites
|
Concept
|
Age Distribution
|
Concept
|
Critical Care
|
Concept
|
Matrix Metalloproteinases
|
Concept
|
Troponin I
|
Concept
|
Ribosomes
|
Academic Article
|
Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction.
|
Academic Article
|
Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure.
|
Academic Article
|
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
|
Academic Article
|
Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload.
|
Academic Article
|
Systolic and diastolic mechanics in stress cardiomyopathy.
|
Academic Article
|
Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction.
|
Academic Article
|
Myocardial fibroblast-matrix interactions and potential therapeutic targets.
|
Academic Article
|
Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction.
|
Academic Article
|
Renal sympathetic denervation for blood pressure control: a review of the current evidence and ongoing studies.
|
Academic Article
|
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
|
Academic Article
|
Developing therapies for heart failure with preserved ejection fraction: current state and future directions.
|
Academic Article
|
Age and SPARC change the extracellular matrix composition of the left ventricle.
|
Academic Article
|
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
|
Academic Article
|
Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
|
Academic Article
|
Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy.
|
Academic Article
|
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
|
Academic Article
|
The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern.
|
Academic Article
|
Impaired left atrial function in heart failure with preserved ejection fraction.
|
Academic Article
|
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
|
Academic Article
|
Adverse left ventricular remodeling in community-dwelling older adults predicts incident heart failure and mortality.
|
Academic Article
|
Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment.
|
Academic Article
|
Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?
|
Academic Article
|
History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction.
|
Academic Article
|
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
|
Academic Article
|
A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction.
|
Academic Article
|
Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction.
|
Academic Article
|
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
|
Academic Article
|
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
|
Academic Article
|
HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis.
|
Academic Article
|
Estrogen-Related Receptor a (ERRa) is required for adaptive increases in PGC-1 isoform expression during electrically stimulated contraction of adult cardiomyocytes in sustained hypoxic conditions.
|
Academic Article
|
Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin.
|
Academic Article
|
Liquid-gel partition chromatography of vitamin A compounds; formation of retinoic acid from retinyl acetate in vivo.
|
Academic Article
|
Dual-source CT imaging to plan transcatheter aortic valve replacement: accuracy for diagnosis of obstructive coronary artery disease.
|
Academic Article
|
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
|
Academic Article
|
Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST).
|
Academic Article
|
A novel ultrasound predictor of pulmonary capillary wedge pressure assessed by the combination of left atrial volume and function: A speckle tracking echocardiography study.
|
Academic Article
|
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
|
Academic Article
|
Response to letters regarding article, "systolic and diastolic mechanics in stress cardiomyopathy".
|
Academic Article
|
Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.
|
Academic Article
|
Left ventricular layer function in hypertension assessed by myocardial strain rate using novel one-beat real-time three-dimensional speckle tracking echocardiography with high volume rates.
|
Academic Article
|
Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization.
|
Academic Article
|
Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage.
|
Academic Article
|
Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
|
Academic Article
|
Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.
|
Academic Article
|
The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
|
Academic Article
|
Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.
|
Academic Article
|
Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure.
|
Academic Article
|
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
|
Academic Article
|
Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
|
Academic Article
|
Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
|
Academic Article
|
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
|
Academic Article
|
Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
|
Academic Article
|
Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model.
|
Academic Article
|
How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
|
Academic Article
|
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
|
Academic Article
|
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
|
Academic Article
|
Is Biventricular Fibrosis the Mediator of Late Complications in Tetralogy of Fallot?
|
Academic Article
|
Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance.
|
Academic Article
|
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial.
|
Academic Article
|
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
|
Academic Article
|
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.
|
Academic Article
|
Lactosylceramide contributes to mitochondrial dysfunction in diabetes.
|
Academic Article
|
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
|
Academic Article
|
Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
|
Academic Article
|
Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium.
|
Academic Article
|
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
|
Academic Article
|
The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio.
|
Academic Article
|
Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.
|
Academic Article
|
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
|
Academic Article
|
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
|
Academic Article
|
Influence of Sacubitril/Valsartan (LCZ696)?on?30-Day Readmission After Heart Failure Hospitalization.
|
Academic Article
|
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
|
Academic Article
|
Efficacy of Sacubitril/Valsartan Relative to?a Prior Decompensation: The PARADIGM-HF Trial.
|
Academic Article
|
Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial.
|
Academic Article
|
Geographic variations in the PARADIGM-HF heart failure trial.
|
Academic Article
|
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
|
Academic Article
|
Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation.
|
Academic Article
|
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
|
Academic Article
|
Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction.
|
Academic Article
|
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
|
Academic Article
|
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
|
Academic Article
|
Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial).
|
Academic Article
|
Diastolic Heart Failure.
|
Academic Article
|
Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
|
Academic Article
|
Could Modification of Titin Contribute to an Answer for Heart Failure With Preserved Ejection Fraction?
|
Academic Article
|
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
|
Academic Article
|
Natriuretic Peptides, 6-Min Walk Test, and?Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials.
|
Academic Article
|
Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction.
|
Academic Article
|
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
|
Academic Article
|
Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure.
|
Academic Article
|
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
|
Academic Article
|
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
|
Academic Article
|
Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
|
Academic Article
|
Palliative Care for Advanced Heart Failure in a Department of Veterans Affairs Regional Hospice Program: Patient Selection, a Treatment Protocol, and Clinical Course.
|
Academic Article
|
Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?
|
Academic Article
|
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
|
Academic Article
|
Evaluation of systolic and diastolic properties of hypertensive heart failure using speckle-tracking echocardiography with high volume rates.
|
Academic Article
|
Angiotensin Receptor Neprilysin Inhibition?in Heart Failure With Preserved?Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
|
Academic Article
|
Declining Risk of Sudden Death in Heart Failure.
|
Academic Article
|
Health-Related Quality of Life Outcomes in PARADIGM-HF.
|
Academic Article
|
Activation of Inflammatory and Pro-Thrombotic Pathways in Acute Stress Cardiomyopathy.
|
Academic Article
|
Heart Rate and Outcomes in Hospitalized?Patients With Heart Failure With Preserved Ejection?Fraction.
|
Academic Article
|
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
|
Academic Article
|
Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.
|
Academic Article
|
Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium.
|
Academic Article
|
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.
|
Academic Article
|
Type of Atrial Fibrillation and Outcomes in?Patients With Heart Failure and Reduced?Ejection?Fraction.
|
Academic Article
|
Cardiac macrophages promote diastolic dysfunction.
|
Academic Article
|
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
|
Academic Article
|
Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of?Heart Failure.
|
Academic Article
|
Increased macrophage-derived SPARC precedes collagen deposition in myocardial fibrosis.
|
Academic Article
|
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
|
Academic Article
|
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
|
Academic Article
|
Elevated Wall Tension Leads to Reduced miR-133a in the Thoracic Aorta by Exosome Release.
|
Academic Article
|
Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association.
|
Academic Article
|
Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry.
|
Academic Article
|
Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
|
Academic Article
|
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
|
Academic Article
|
Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease.
|
Academic Article
|
Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).
|
Academic Article
|
Correction: Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry.
|
Academic Article
|
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
|
Academic Article
|
Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction.
|
Academic Article
|
Safety and Feasibility of a Nocturnal Heart Rate Elevation-Exploration of a Novel Treatment Concept.
|
Academic Article
|
Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate.
|
Academic Article
|
Heart failure with preserved ejection fraction in Asia.
|
Academic Article
|
First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF.
|
Academic Article
|
Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.
|
Academic Article
|
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
|
Academic Article
|
Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al.
|
Academic Article
|
Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee.
|
Academic Article
|
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
|
Academic Article
|
Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review.
|
Academic Article
|
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
|
Academic Article
|
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.
|
Academic Article
|
The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
|
Academic Article
|
Heart Failure With Preserved Ejection Fraction in the Young.
|
Academic Article
|
Differential Impact of Heart Failure With?Reduced Ejection Fraction on?Men?and?Women.
|
Academic Article
|
Income Inequality and Outcomes in Heart?Failure: A Global Between-Country Analysis.
|
Academic Article
|
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
|
Academic Article
|
Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients?With HFrEF.
|
Academic Article
|
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The?PARADIGM-HF?Trial.
|
Academic Article
|
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
|
Academic Article
|
Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
|
Academic Article
|
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
|
Academic Article
|
Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF).
|
Academic Article
|
Should We Test for Diastolic Dysfunction? How and How Often?
|
Academic Article
|
Mitochondrial biogenesis induced by the ?2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury.
|
Academic Article
|
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.
|
Academic Article
|
Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure.
|
Academic Article
|
Health-Related Quality of Life in Heart?Failure With Preserved Ejection?Fraction: The PARAGON-HF Trial.
|
Academic Article
|
Changes in the crystallographic structures of cardiac myosin filaments detected by polarization-dependent second harmonic generation microscopy.
|
Academic Article
|
Age-Related Characteristics and Outcomes of Patients With Heart?Failure With Preserved Ejection Fraction.
|
Academic Article
|
Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
|
Academic Article
|
Repetitive Acute Hemodynamic Load: Progression From Systolic Decompensation to Cellular/Extracellular Compensation to Diastolic Decompensation.
|
Academic Article
|
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
|
Academic Article
|
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.
|
Academic Article
|
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
|
Academic Article
|
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
|
Academic Article
|
Echocardiographic Features of Patients?With Heart?Failure and Preserved?Left Ventricular Ejection Fraction.
|
Academic Article
|
Sex-Related Differences in Heart Failure With Preserved Ejection Fraction.
|
Academic Article
|
Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction.
|
Academic Article
|
Seipin Knockout Mice Develop Heart?Failure With Preserved Ejection?Fraction.
|
Academic Article
|
Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure.
|
Academic Article
|
Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
|
Academic Article
|
SPARC production by bone marrow-derived cells contributes to myocardial fibrosis in pressure overload.
|
Academic Article
|
The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice.
|
Academic Article
|
Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices.
|
Academic Article
|
The Vexing Problem of HFpEF?Therapeutics: Inching Toward Success.
|
Academic Article
|
Changes in Myocardial Microstructure and Mechanics With Progressive Left?Ventricular Pressure Overload.
|
Academic Article
|
Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation.
|
Academic Article
|
Pressure overload generates a cardiac-specific profile of inflammatory mediators.
|
Academic Article
|
Prediction of heart failure hospitalizations based on the direct measurement of intrathoracic impedance.
|
Concept
|
Machine Learning
|
Concept
|
Remote Sensing Technology
|
Concept
|
Cardio-Renal Syndrome
|
Concept
|
Multimorbidity
|
Concept
|
Diabetic Cardiomyopathies
|
Concept
|
Mitral Valve Annuloplasty
|
Concept
|
Cardiac Resynchronization Therapy
|
Concept
|
Cardiac Resynchronization Therapy Devices
|
Concept
|
Implantable Neurostimulators
|
Concept
|
Myofibroblasts
|
Concept
|
Adrenergic beta-2 Receptor Agonists
|
Concept
|
Pandemics
|
Concept
|
Adenosine A1 Receptor Antagonists
|
Concept
|
LIM-Homeodomain Proteins
|
Concept
|
Real-Time Polymerase Chain Reaction
|
Concept
|
Weight Reduction Programs
|
Concept
|
Discoidin Domain Receptors
|
Concept
|
Discoidin Domain Receptor 1
|
Concept
|
Walk Test
|
Concept
|
Patient Reported Outcome Measures
|
Concept
|
Insulins
|
Concept
|
Caspase Inhibitors
|
Concept
|
Matrix Metalloproteinase Inhibitors
|
Concept
|
Patient Acuity
|
Concept
|
Cardiac Catheters
|
Concept
|
Patient Outcome Assessment
|
Concept
|
Connectin
|
Concept
|
Observational Studies as Topic
|
Concept
|
Endothelin Receptor Antagonists
|
Concept
|
Non-Randomized Controlled Trials as Topic
|
Concept
|
Transcatheter Aortic Valve Replacement
|
Concept
|
Cardiotoxicity
|
Concept
|
ErbB Receptors
|
Concept
|
Vascular Remodeling
|
Concept
|
ADAMTS1 Protein
|
Concept
|
Frailty
|
Concept
|
Rosuvastatin Calcium
|
Concept
|
Valsartan
|
Concept
|
Formoterol Fumarate
|
Concept
|
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
|
Concept
|
Guanylyl Cyclase C Agonists
|
Concept
|
S100 Calcium-Binding Protein A4
|
Concept
|
Interleukin-1 Receptor-Like 1 Protein
|
Concept
|
Retinoic Acid Receptor alpha
|
Concept
|
Homeobox Protein Nkx-2.5
|
Concept
|
Hemodynamic Monitoring
|
Concept
|
Angiotensin Receptor Antagonists
|
Concept
|
Drug Substitution
|
Academic Article
|
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
|
Academic Article
|
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart?Failure With Preserved Ejection Fraction.
|
Academic Article
|
Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
|
Academic Article
|
Myocardial Infarction in Heart?Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
|
Academic Article
|
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
|
Academic Article
|
Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
|
Academic Article
|
Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart?Failure Position Paper.
|
Academic Article
|
Covariate adjusted reanalysis of the I-Preserve trial.
|
Academic Article
|
Reply: Different Phenotype Characterization in PARAGON-HF: An Unresolved Puzzle in Patients With HFpEF.
|
Academic Article
|
The prevalence and importance of frailty in heart failure with reduced ejection fraction?-?an analysis of PARADIGM-HF and ATMOSPHERE.
|
Academic Article
|
Baroreflex Activation Therapy in Patients With Heart?Failure With Reduced Ejection Fraction.
|
Academic Article
|
Loop Diuretic Prescription and 30-Day?Outcomes in Older Patients With?Heart?Failure.
|
Academic Article
|
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart?Failure Cause: A PARADIGM-HF Analysis.
|
Academic Article
|
Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension.
|
Academic Article
|
Reply: Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF.
|
Academic Article
|
Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction.
|
Academic Article
|
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial.
|
Academic Article
|
Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis.
|
Academic Article
|
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
|
Academic Article
|
Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE.
|
Academic Article
|
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.
|
Academic Article
|
Serum potassium in the PARADIGM-HF trial.
|
Academic Article
|
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
|
Academic Article
|
Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population.
|
Academic Article
|
Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF.
|
Academic Article
|
Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
|
Academic Article
|
Prediction of worsening heart failure events and all-cause mortality using an individualized risk stratification strategy.
|
Academic Article
|
Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion.
|
Academic Article
|
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.
|
Academic Article
|
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
|
Academic Article
|
INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction.
|
Academic Article
|
Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials.
|
Academic Article
|
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
|
Academic Article
|
Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
|
Academic Article
|
Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?
|
Academic Article
|
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
|
Academic Article
|
Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization.
|
Academic Article
|
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
|
Academic Article
|
A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone.
|
Academic Article
|
Pragmatic Weight Management Program for Patients With Obesity and Heart Failure With Preserved Ejection Fraction.
|
Academic Article
|
Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States.
|
Academic Article
|
Incidence and Outcomes of Pneumonia in Patients With Heart?Failure.
|
Academic Article
|
From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited.
|
Academic Article
|
Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE.
|
Academic Article
|
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.
|
Academic Article
|
Integrating High-Sensitivity Troponin T and?Sacubitril/Valsartan Treatment in?HFpEF: The PARAGON-HF Trial.
|
Academic Article
|
Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction.
|
Academic Article
|
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial.
|
Academic Article
|
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF.
|
Academic Article
|
Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction.
|
Academic Article
|
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF.
|
Academic Article
|
Atrial Fibrillation in Heart?Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
|
Academic Article
|
Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF.
|
Academic Article
|
Mechanisms that limit regression of myocardial fibrosis following removal of left ventricular pressure overload.
|
Academic Article
|
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
|
Academic Article
|
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure.
|
Academic Article
|
Phenotypic characterization of primary cardiac fibroblasts from patients with HFpEF.
|
Academic Article
|
Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes.
|
Academic Article
|
Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure.
|
Academic Article
|
The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.
|
Academic Article
|
Ensemble machine learning model identifies patients with HFpEF from matrix-related plasma biomarkers.
|
Academic Article
|
Baroreflex activation therapy with the Barostim? device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials.
|
Academic Article
|
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.
|
Academic Article
|
And the band played on: persistent fibrosis after unbanding reveals sex-dependent differences in rats.
|
Academic Article
|
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.
|
Academic Article
|
Health-Related Quality of Life Outcomes in PARAGON-HF.
|
Academic Article
|
Hemodynamically-Guided Management of Heart?Failure Across the Ejection?Fraction Spectrum: The GUIDE-HF Trial.
|
Academic Article
|
Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction.
|
Academic Article
|
In vitro bioreactor for mechanical control and characterization of tissue constructs.
|
Academic Article
|
Temporal Characteristics of Device-Based Individual and Integrated?Risk Metrics in Patients With?Chronic?Heart?Failure.
|
Academic Article
|
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients with Heart Failure.
|
Academic Article
|
Neuromodulation devices for heart failure.
|
Academic Article
|
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation.
|
Academic Article
|
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Reduced Ejection Fraction.
|
Academic Article
|
Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
|
Academic Article
|
Exercise-Induced Left Atrial Hypertension?in Heart?Failure With Preserved Ejection Fraction.
|
Academic Article
|
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.
|
Academic Article
|
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox.
|